Biomarkers discovered to cisplatin-resistant cancer cells

Scientists at University Paris Descartes in Paris, France, identified biomarkers in non-small cell lung cancer cells that prove resistant to the chemotherapy drug cisplatin. Cells that showed resistance all had high, hyperactivated levels of the protein poly (ADP-ribose) polymerase 1 (PARP1), plus poly (ADP-ribosyl) (PAR). These biomarkers proved themselves even more once the investigators treated cisplatin-resistant non-small cell lung cancer cell lines with two PARP inhibitors--the cancer cells died. "This has clear implications for new treatment regimens and for developing biomarkers of response to cisplatin," researcher Guido Kroemer said in a statement. Details of their work are published in the journal Cancer Research. Release

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.